LA HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
A federal judge on Thursday denied Amgen Inc.’s bid to stop the sale of a biosimilar form of Neupogen, the company’s infection-fighting blockbuster drug for cancer patients.
Shares of Herbalife Ltd., the downtown Los Angeles nutritional supplement company, rose Wednesday after a judge dismissed a lawsuit brought by shareholders alleging they lost money because the business was an illegal pyramid scheme.
Two Playa del Rey therapists were arrested Tuesday for health insurance fraud after allegedly billing Anthem Blue Cross for services amounting to $3.5 million that they never provided, according to the California Department of Insurance.
Santa Monica biopharmaceutical firm Kite Pharma Inc. has acquired a Dutch biotech company in a deal valued at more than $21 million, using the private firm to establish its European headquarters in Amsterdam.
The Federal Bureau of Investigation and federal prosecutors are examining people hired by hedge fund manager William Ackman about potential manipulation of Herbalife Ltd. stock, according to the Wall Street Journal.
Amgen Inc. plans to lay off 300 workers at its Onyx subsidiary in South San Francisco, and transfer others to its Thousand Oaks headquarters.
Prime Healthcare Services has withdrawn its $843 million bid for Daughters of Charity’s ailing hospitals, including two in L.A. County, in the face of stringent conditions imposed by state Attorney General Kamala Harris.
Kythera Biopharmaceuticals Inc. announced on Tuesday a $125 million secondary offering as it anticipates FDA approval of its lead drug candidate, a drug that reduces double chins.
A Food and Drug Administration panel on Monday recommended approval of Kythera Biopharmaceuticals Inc.’s novel treatment for chin fat.
Amgen Inc. will face new competition after Novartis AG secured the first-ever FDA approval to sell a “biosimilar” drug – provided it can overcome a legal challenge by the Thousand Oaks company.
Pasadena biotechnology company Arrowhead Research Corp. announced today that it had struck a deal to acquire the RNAi research and development portfolio of drug maker Novartis in a deal valued at about $35 million.
Cannabis investment firm Lizada Capital signed a $15 million deal Wednesday that will make it Medbox’s largest shareholder.
Caren Mason, who was elected to implantable lens maker Staar Surgical Co.’s board last June, was named Tuesday as chief executive, replacing Barry Caldwell who retired March 1.
If Herbalife Ltd. Chief Executive Michael Johnson sounded upbeat on the company’s recent earnings call, it likely had nothing to do with his 2014 compensation.
Herbalife Ltd., the embattled downtown Los Angeles nutritional supplement company, reported its fourth quarter earnings, with some disappointing results, after markets closed Thursday.